£

Chronic myeloid leukaemia can sometimes stop responding to certain treatments and occasionally it can become a very aggressive disease. In this project, the team want to understand how we can tackle this.

Headshot of David Vetrie

Professor David Vetrie

Project information

Lead researcher

Professor David Vetrie, University of Glasgow

Research team
  • A team at University of Glasgow
Related conditions
  • Myeloma
  • Childhood leukaemias
  • Leukaemia
Research type
  • Non-clinical
Region
  • Scotland
Grant awarded
  • Programme Continuity Grant
Status
Completed
Funding award date
November 2021
Amount awarded

£300,000

Project completion date
October 2024

The challenge

Chronic myeloid leukaemia (CML) is a type of blood cancer caused because there is an error in a blood stem cell. This stem cell is the earliest version of any of our blood cells and can become many different cells. If these stem cells become faulty, as they do in CML, it can mean blood cells don’t work properly.

Luckily, we have treatments that can keep this cancer under control for many people, but some cancers can stop responding to this treatment and others can become more aggressive. In this project the team want to find ways to overcome this.

The project

In this study, Professor David Vetrie and his team want to find ways to treat people whose cancers have stopped responding to treatment. They also want to understand more about how and why CML suddenly becomes very aggressive, to try and find ways to stop this from happening.

The team have identified a protein inside our cells that they think are responsible for these two things happening and will see whether targeting this in the lab.

The future

If the findings from this project are positive, we could find new ways to treat CML that's stopped responding to treatment and we may also find new ways to treat the disease if it become particularly aggressive.

Help us beat blood cancer by funding a research project

  • Could help eight people newly diagnosed with blood cancer understand their condition.
  • Could help researchers study blood cancer cells to develop new treatments and improve early diagnosis.
  • Could help scientists identify genetic patterns in tumour samples to better understand how genes contribute to the development of blood cancer.
Donate